Comparing SG&A Expenses: Viking Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech firms: Viking Therapeutics, Inc. and Celldex Therapeutics, Inc., from 2014 to 2023.

Key Insights

Over the past decade, Celldex Therapeutics has consistently maintained higher SG&A expenses compared to Viking Therapeutics. Notably, in 2023, Celldex's expenses surged by approximately 13% from the previous year, reaching a peak of $30.9 million. In contrast, Viking Therapeutics experienced a dramatic increase of over 130% in the same period, culminating in $37 million.

Trends and Implications

The data reveals a significant shift in Viking's financial strategy, possibly indicating aggressive expansion or increased operational activities. Meanwhile, Celldex's steady expenditure suggests a more stable approach. These trends offer valuable insights into each company's strategic priorities and market positioning.